Page 3 - கெவன் ஷோகாட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கெவன் ஷோகாட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கெவன் ஷோகாட் Today - Breaking & Trending Today

Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie


Share this article
Share this article
SAN FRANCISCO, March 2, 2021 /PRNewswire/  Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, announced today that AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin s lead PINK1 compound. Based on technology discovered at UCSF by Mitokinin co-founders Nicholas Hertz and Kevan Shokat, Mitokinin moved into MBC BioLabs San Francisco in September 2017 with Series A funding from a syndicate led by Mission BioCapital.   
Mitokinin s novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson s disease.   ....

San Francisco , United States , Nicholas Hertz , Michaeld Taylor , Kevan Shokat , Mitokinin Inc , Mission Biocapital , Partner At Mission Biocapital , Labs San Francisco , Daniel De Roulet , Executive Chairman , Operating Partner , Pfizer Ventures , சான் பிரான்சிஸ்கோ , ஒன்றுபட்டது மாநிலங்களில் , நிக்கோலஸ் ஹெர்ட்ஸ் , கெவன் ஷோகாட் , ஆய்வகங்கள் சான் பிரான்சிஸ்கோ , டேனியல் டி சில்லி , நிர்வாகி தலைவர் , இயங்குகிறது கூட்டாளர் , ஃபைசர் முயற்சிகள் ,

How scientists shot down cancer's 'death star'


Gina Kolata, The New York Times
Published: 06 Feb 2021 04:40 PM BdST
Updated: 06 Feb 2021 04:40 PM BdST
Cancer cells. www.en.wikipedia.org
After 40 years of effort, researchers have finally succeeded in switching off one of the most common cancer-causing genetic mutations in the human body. The finding promises to improve treatment for thousands of patients with lung and colorectal cancer, and may point the way to a new generation of drugs for cancers that resist treatment.
);
}
The finding has already led to a new medication, sotorasib, by drugmaker Amgen. Other companies are close behind with their own versions.
Amgen tested its drug in patients with the most common type of lung cancer, called non-small cell cancer. The disease is diagnosed in 228,000 Americans a year, and for most patients in the advanced stages, there is no cure. ....

New York , United States , Dana Farber Cancer Institute , University Of Texas , San Francisco , Bruce Johnson , Kevan Shokat , John Minna , David Reese , University Of California , York Times Company , University Of Texas Southwestern Medical Centre , World Conference , Texas Southwestern Medical Centre , Death Star , New York Times , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் , சான் பிரான்சிஸ்கோ , காயங்கள் ஜான்சன் , கெவன் ஷோகாட் , ஜான் மின்னா , டேவிட் ரீஸ் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா ,